Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in HER2-Overexpressed Biliary Tract Cancer
NCT04329429Phase 2Active, not recruiting
- Sponsor
- RemeGen
- Start
- Aug 2020
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in biliary tract cancer (BTC), sponsored by RemeGen. Started Aug 2020; status: active, not recruiting.
02
Drugs
disitamab vedotin
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04329429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329429.